Intervention not reported
FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 0.44 [0.11, 1.72]1 study · 32 participantsGRADE not reported